CANAAN X L.P. 4
4 · IDEAYA Biosciences, Inc. · Filed May 28, 2019
Insider Transaction Report
Form 4
CANAAN X L.P.
10% Owner
Transactions
- Conversion
Common Stock
2019-05-28+1,658,164→ 1,658,164 total - Purchase
Common Stock
2019-05-28$10.00/sh+400,000$4,000,000→ 2,660,713 total - Conversion
Common Stock
2019-05-28+602,549→ 2,260,713 total - Conversion
Series A Preferred Stock
2019-05-28−1,658,164→ 0 total→ Common Stock (1,658,164 underlying) - Conversion
Series B Preferred Stock
2019-05-28−602,549→ 0 total→ Common Stock (602,549 underlying)
Footnotes (4)
- [F1]Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
- [F2]Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.
- [F3]The reported securities are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.
- [F4]Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.